Version history

{
  "session_id": "sess_hypdebate_h_b662ff65_20260427_112802",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "content": "\n\n## Expert Assessment: STMN2 Splice Switching for ALS-FTD-AD\n\n### Druggability: HIGH\n\nThis hypothesis targets a **highly tractable** mechanism. The poison exon inclusion event is straightforward to block with antisense oligonucleotides (ASOs), analogous to the successful nusinersen (Spinraza) approach for SMN2 splicing in SMA. Preclinical data in iPSC-derived neurons demonstrates robust rescue of STMN2 levels and axonal protection upon ASO-mediated exon skipping. Splice-switching ASOs represent well-established platform technology with known pharmacokinetic-pharmacodynamic relationships.\n\n**Specific compounds in development** include ASO candidates targeting the STMN2 splice branchpoint/acceptor site (Biogen/Ionis collaboration). Published preclinical work (Klim et al., 2019; Volvo et al., 2021) establishes the mechanistic proof-of-concept in human neurons.\n\n### Feasibility: MODERATE-HIGH\n\nThe mechanism is biologically compelling—TDP-43 loss directly causes STMN2 dysregulation, and stathmin-2 is a validated axonal maintenance factor. However, human validation remains limited. The therapeutic index concern is real: stathmin-2 is a microtubule-destabilizing protein, and constitutive knockdown may impair normal axonal transport. The primary uncertainty is whether STMN2 correction alone is sufficient or whether concurrent TDP-43 functional restoration is needed.\n\n### Competitive Landscape\n\nMultiple players pursue TDP-43 biology: Biogen has active ASO programs (including TDP-43 itself); Ionis has CNS-penetrant ASO platforms; Wave Life Sciences develops small-molecule splicing modulators. STMN2-specific approaches face competition but remain differentiation-worthy if efficacy proves superior to broader TDP-43 strategies.\n\n### Safety Concerns\n\n- **On-target CNS toxicity**: Microtubule dynamics disruption in surviving neurons\n- **ASO class effects**: Thrombocytopenia, hepatotoxicity, CSF pleocytosis\n- **Delivery limitation**: Intrathecal dosing required; uneven spinal cord distribution\n- **Biomarker gap**: No validated pharmacodynamic marker for target engagement in humans\n\n### Timeline Estimate\n\nPhase I readiness: 2-3 years with IND-enabling studies. First-in-human trials likely in ALS (easier enrollment, established endpoints) before FTD-AD expansion. Total development: 6-8 years minimum.\n\n**Verdict**: Mechanistically sound and druggable, but require careful dose-titration to establish therapeutic window before committing to full development program."
}